Autres langues Matricelf Ltd

Actions

MTLF

IL0011767915

Recherche biotechnologique et médicale

Marché Fermé - TEL AVIV STOCK EXCHANGE Autres places de cotation 12:44:13 31/07/2026			Varia. 5j.	Varia. 1 janv.
248,20 ^ILa	+1,31%		+2,56%	-54,95%

09/07	Matricelf Ltd. reçoit l'autorisation de débuter l'identification des patients et les prélèvements sanguins pour sa première étude clinique sur les lésions de la moelle épinière	CI
22/06	Matricelf lance une étude d'efficacité pré-IND pour son implant de tissu neural humain destiné aux lésions chroniques de la moelle épinière	CI

Autres langues

09/07	Matricelf Ltd. Receives Approval to Begin Patient Identification and Blood Collection for Planned First-In-Human Spinal Cord Injury Study
09/07	Matricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing Milestones
23/06	Matricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord Injury
22/06	Matricelf Initiates Ind Enabling Efficacy Study for Engineered Human Neural Tissue Implant in Chronic Spinal Cord Injury
17/06	Matricelf Completes GLP Safety Study for Engineered Neural Tissue Implant
30/03	Matricelf Ltd. Enters into Collaborative Research Agreement with CiRA Foundation
24/03	Matricelf Ltd Reports Earnings Results for the Full Year Ended December 31, 2025
24/03	Matricelf and Sheba Medical Center Enter Strategic Collaboration to Advance First in Human Clinical Program in Spinal Cord Injury
24/03	Matricelf Ltd Auditor Raises 'Going Concern' Doubt
04/03	Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord Implant
03/03	Matricelf Ltd. Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy
03/03	Matricelf Ltd. (Tase Mtlf) signs MoU to establish subsidiary for commercialization of Parkinson's disease therapy
03/03	Matricelf Ltd. (TASE: MTLF) Signs MOU to Establish Subsidiary for Commercialization of Parkinson's Disease Therapy
02/03	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board
27/02	Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of Directors
27/02	Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board
26/02	Matricelf Ltd. (TASE: MTLF) Reports 2025 Milestones and Outlines 2026 Strategic Roadmap Toward First-in-Human Spinal Cord Implantation
21/08/25	Tel Aviv University: Israeli Breakthrough: First Human Trial of Engineered Spinal Cord
03/08/25	Matricelf Ltd Reports Earnings Results for the Half Year Ended June 30, 2025
12/03/25	Cellino and Matricelf, New Hope for Spinal Cord Injuries
11/03/25	Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments
11/03/25	Cellino and Matricelf Announce Global Collaboration to Scale Personalized Spinal Cord Injury Treatments
27/03/24	Matricelf : INVESTORS PRESENTATION